Pfizer Key Development Products Berobenatide/PF3944, formerly MET-097i Long-acting GLP-1 receptor agonist MET-233i Amylin-related drug Combination of Berobenatide and MET-233i Oral small-molecule GLP-1 candidate Current Positioning Danuglipron, which was listed as a core development product in the previous edition, was discontinued in April 2025
Michael DeShields, MD, the clinical adviser of the Discovery Institute in New Jersey, says access to Wegovy has improved over time, but insurance companies like Aetna still cover it inconsistently
But GLP-1 medications arent the only way to treat Type 2 diabetes
Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial
Many of our patients visit from nearby Brookfield and Pewaukee, but we serve all surrounding areas in Wisconsin
According to the NHS, a lack of B12 may lead to anaemia, weakness, and even memory problems
